Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drug Products: Biologics, Biosimilars and Interchangeables01:28

Drug Products: Biologics, Biosimilars and Interchangeables

360
Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
360
Antiasthma Drugs: Leukotriene Modifiers01:19

Antiasthma Drugs: Leukotriene Modifiers

2.3K
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
2.3K
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

362
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
362
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

994
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
994
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

863
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
863
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

726
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
726

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Inborn Errors of Immunity Presenting with Early-Onset Severe Atopy.

Medicina (Kaunas, Lithuania)·2025
Same author

Etiology, management, and outcomes of pediatric telogen effluvium: A single-center study in the United States.

Pediatric dermatology·2022
Same author

Mosaic <i>TP63</i> variant and associated ectodermal dysplasia features.

JAAD case reports·2021
Same author

Provider perceptions and practices for appearance-related psychosocial distress caused by dermatologic disease in children.

Pediatric dermatology·2021
Same author

Acute urticaria preceding other COVID-19-associated manifestations-A case report.

Pediatric dermatology·2021
Same author

Hydrolysed formula, delayed food introduction and fatty acids for atopic dermatitis prevention in infancy.

Acta paediatrica (Oslo, Norway : 1992)·2020
Same journal

Adverse Childhood Experiences and Pediatric Dermatology: Implications for Care, Equity, and Research.

Pediatric dermatology·2026
Same journal

State-of-the-Art Review: Vaccination in Pediatric Dermatology Patients Receiving Immunosuppressive or Immunomodulatory Therapy: A Review.

Pediatric dermatology·2026
Same journal

Multisystem Mucosal Morbidity in Recessive Dystrophic Epidermolysis Bullosa Inversa.

Pediatric dermatology·2026
Same journal

Infantile Transient Smooth Muscle Contraction of the Skin in Two Sisters.

Pediatric dermatology·2026
Same journal

Are 2021 CMS Changes Enough to Address the Pediatric Dermatology Crisis?

Pediatric dermatology·2026
Same journal

Annular Eruption in 12-Year-Old Boy.

Pediatric dermatology·2026
See all related articles

Related Experiment Video

Updated: Apr 16, 2026

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
11:39

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

Published on: July 11, 2013

39.7K

Biologic response modifiers and pediatric psoriasis.

Fernanda Bellodi Schmidt1, Kara N Shah1,2,3

  • 1Division of Dermatology, Cincinnati Children's Hospital, Cincinnati, Ohio.

Pediatric Dermatology
|March 3, 2015
PubMed
Summary
This summary is machine-generated.

Biologic therapies like etanercept show promise for treating pediatric psoriasis, though U.S. approval is pending. Existing data on these treatments for other pediatric inflammatory conditions support their safety.

More Related Videos

Generation of Immature, Mature and Tolerogenic Dendritic Cells with Differing Metabolic Phenotypes
06:09

Generation of Immature, Mature and Tolerogenic Dendritic Cells with Differing Metabolic Phenotypes

Published on: June 22, 2016

24.2K
Genome-wide Analysis of HDAC Inhibitor-mediated Modulation of microRNAs and mRNAs in B Cells Induced to Undergo Class-switch DNA Recombination and Plasma Cell Differentiation
11:06

Genome-wide Analysis of HDAC Inhibitor-mediated Modulation of microRNAs and mRNAs in B Cells Induced to Undergo Class-switch DNA Recombination and Plasma Cell Differentiation

Published on: September 20, 2017

6.6K

Related Experiment Videos

Last Updated: Apr 16, 2026

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
11:39

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

Published on: July 11, 2013

39.7K
Generation of Immature, Mature and Tolerogenic Dendritic Cells with Differing Metabolic Phenotypes
06:09

Generation of Immature, Mature and Tolerogenic Dendritic Cells with Differing Metabolic Phenotypes

Published on: June 22, 2016

24.2K
Genome-wide Analysis of HDAC Inhibitor-mediated Modulation of microRNAs and mRNAs in B Cells Induced to Undergo Class-switch DNA Recombination and Plasma Cell Differentiation
11:06

Genome-wide Analysis of HDAC Inhibitor-mediated Modulation of microRNAs and mRNAs in B Cells Induced to Undergo Class-switch DNA Recombination and Plasma Cell Differentiation

Published on: September 20, 2017

6.6K

Area of Science:

  • Dermatology
  • Immunology
  • Pediatrics

Background:

  • Biologic response modifiers (biologics) are effective for adult psoriasis.
  • Limited regulatory approval exists for pediatric psoriasis treatment in the US and EU.
  • Tumor necrosis factor-alpha (TNF-α) antagonists are used for other pediatric inflammatory diseases.

Purpose of the Study:

  • To review the literature supporting the use of biologics for pediatric psoriasis.
  • To assess the safety and efficacy of biologics in children with psoriasis.

Main Methods:

  • Literature review of case reports, case series, and clinical trials.
  • Examination of data from studies on etanercept, adalimumab, infliximab, and ustekinumab.
  • Analysis of safety data from pediatric inflammatory disease treatments.

Main Results:

  • Evidence from case reports, series, and a large trial supports etanercept for pediatric psoriasis.
  • No biologics are FDA-approved for pediatric psoriasis in the US; etanercept is approved in the EU.
  • Safety profiles of etanercept, adalimumab, and infliximab are supported by their use in other pediatric inflammatory conditions.

Conclusions:

  • Biologics, particularly etanercept, show potential for treating pediatric psoriasis.
  • Further research and regulatory action are needed for broader US approval of biologics in pediatric psoriasis.
  • The safety of TNF-α antagonists in children is supported by evidence from other inflammatory diseases.